

1 A bill to be entitled
 2 An act relating to controlled substances; creating s.
 3 893.055, F.S.; providing definitions; requiring the Agency
 4 for Health Care Administration to establish a statewide,
 5 comprehensive electronic system to monitor the prescribing
 6 and dispensing of controlled substances listed in Schedule
 7 II, Schedule III, or Schedule IV; providing reporting
 8 requirements; requiring the agency to notify certain
 9 dispensers and prescribers of the implementation date for
 10 the reporting of controlled substances; specifying
 11 circumstances under which a pharmacy or practitioner is
 12 exempt from participating in the system; requiring
 13 prescribing or dispensing pharmacists and practitioners to
 14 submit information in a certain format; providing a
 15 penalty; requiring that the department and regulatory
 16 boards adopt rules; requiring that all costs incurred by
 17 the agency be paid through federal, private, or grant
 18 funding sources; providing an effective date.

19
 20 Be It Enacted by the Legislature of the State of Florida:

21
 22 Section 1. Section 893.055, Florida Statutes, is created
 23 to read:

24 893.055 Electronic-monitoring system for prescription of
 25 controlled substances listed in Schedule II, Schedule III, or
 26 Schedule IV.--

27 (1) As used in this section, the term:

28 (a) "Agency" means the Agency for Health Care

HB 897

2009

29 Administration.

30 (b) "Department" means the Department of Health.

31 (c) "Pharmacy" means any pharmacy that is subject to
32 licensure or regulation by the department pursuant to chapter
33 465 and that dispenses or delivers a controlled substance
34 included in Schedule II, Schedule III, or Schedule IV in s.
35 893.03 to a patient in this state.

36 (2) By June 30, 2010, the agency shall design and
37 establish an electronic system consistent with standards of the
38 American Society for Automation in Pharmacy to monitor the
39 prescribing of controlled substances listed in Schedule II,
40 Schedule III, or Schedule IV in s. 893.03 by health care
41 practitioners and the dispensing of such controlled substances
42 to an individual by a dispensing practitioner pursuant to
43 chapter 465 or a pharmacy permitted or registered by the Board
44 of Pharmacy pursuant to chapter 465.

45 (3) Each time a controlled substance listed in Schedule
46 II, Schedule III, or Schedule IV is dispensed to an individual,
47 the controlled substance must be reported to the agency through
48 the system as soon thereafter as possible, but not more than 15
49 days after the date the controlled substance is dispensed. A
50 pharmacy or dispensing practitioner may meet the reporting
51 requirements of this section by providing to the agency in
52 written or any electronic or magnetic format, including, but not
53 limited to, electronic submission via the Internet or magnetic
54 disc or tape, each controlled substance listed in Schedule II,
55 Schedule III, or Schedule IV which it dispenses.

56 (4) The agency shall notify each dispenser and prescriber

HB 897

2009

57 subject to the reporting requirements in this section of the
58 implementation date for the reporting requirements as set forth
59 in the rules of the agency.

60 (5) This section does not apply to controlled substances:

61 (a) Administered by a health care practitioner directly to
62 a patient.

63 (b) Dispensed by a health care practitioner authorized to
64 prescribe controlled substances directly to a patient and
65 limited to an amount adequate to treat the patient for a period
66 of not more than 72 hours.

67 (c) Dispensed by a health care practitioner or a
68 pharmacist to an inpatient of a facility that holds an
69 institutional pharmacy permit.

70 (d) Ordered from an institutional pharmacy permitted under
71 s. 465.019 in accordance with the institutional policy for such
72 controlled substances or drugs.

73 (e) Dispensed by a pharmacist or administered by a health
74 care practitioner to a patient or resident receiving care from a
75 hospital, nursing home, assisted living facility, home health
76 agency, hospice, or intermediate care facility for the
77 developmentally disabled which is licensed in this state.

78 (6) The data required to be reported under this section
79 shall be determined by the department by rule and may include,
80 but is not limited to, any data required under s. 893.04.

81 (7) A practitioner or pharmacist who dispenses a
82 controlled substance listed in Schedule II, Schedule III, or
83 Schedule IV in s. 893.03 must submit the information required by
84 this section in an electronic or other format approved by rule

85 of the agency. The cost to the dispenser in submitting the
86 information required by this section may not be material or
87 extraordinary. Costs not considered to be material or
88 extraordinary include, but are not limited to, regular postage,
89 compact discs, zip-drive storage, regular electronic mail,
90 magnetic tapes, diskettes, and facsimile charges. The
91 information submitted to the agency under this section may be
92 transmitted to any person or agency authorized to receive it
93 pursuant to chapter 119, and that person or agency may maintain
94 the information received for up to 24 months before purging the
95 information from its records. All transmissions required by this
96 subsection must comply with relevant privacy and security laws
97 of the state and federal government. However, any authorized
98 agency receiving such information may maintain it for longer
99 than 24 months if the information is pertinent to an ongoing
100 investigation or prosecution.

101 (8) Any person who knowingly fails to report the
102 dispensing of a controlled substance listed in Schedule II,
103 Schedule III, or Schedule IV as required by this section commits
104 a misdemeanor of the first degree, punishable as provided in s.
105 775.082 or s. 775.083.

106 (9) The department and the regulatory boards for the
107 health care practitioners subject to this section shall adopt
108 rules to administer this section.

109 (10) All costs incurred by the agency in administering the
110 prescription-monitoring system shall be through federal,
111 private, or grant funding applied for by the state. The agency
112 and state government shall cooperate in seeking grant funds at

HB 897

2009

113 | no cost to the agency.

114 | Section 2. This act shall take effect July 1, 2009.